Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Antimüllerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer.

Anderson RA, Wallace WH.

Fertil Steril. 2013 May;99(6):1469-75. doi: 10.1016/j.fertnstert.2013.03.014. Epub 2013 Mar 27. Review.

PMID:
23541317
2.

Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors.

Lunsford AJ, Whelan K, McCormick K, McLaren JF.

Fertil Steril. 2014 Jan;101(1):227-31. doi: 10.1016/j.fertnstert.2013.08.052. Epub 2013 Sep 29.

PMID:
24083876
3.

Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone.

Toner JP, Seifer DB.

Fertil Steril. 2013 Jun;99(7):1825-30. doi: 10.1016/j.fertnstert.2013.03.001. Epub 2013 Mar 30. Review.

PMID:
23548941
4.

Tests for ovarian reserve: reliability and utility.

Domingues TS, Rocha AM, Serafini PC.

Curr Opin Obstet Gynecol. 2010 Aug;22(4):271-6. doi: 10.1097/GCO.0b013e32833b4f5c. Review.

PMID:
20543692
5.

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis.

Tal R, Tal O, Seifer BJ, Seifer DB.

Fertil Steril. 2015 Jan;103(1):119-30.e3. doi: 10.1016/j.fertnstert.2014.09.041. Epub 2014 Oct 24. Review.

PMID:
25450298
6.

Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.

Sepúlveda M, Ros C, Martínez-Lapiscina EH, Solà-Valls N, Hervàs M, Llufriu S, La Puma D, Casals E, Blanco Y, Villoslada P, Graus F, Castelo-Branco C, Saiz A.

Mult Scler. 2016 Apr;22(4):564-8. doi: 10.1177/1352458515602339. Epub 2015 Sep 11.

PMID:
26362892
7.

Impact of cancer therapies on ovarian reserve.

Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, Vance A, Ginsberg JP.

Fertil Steril. 2012 Jan;97(1):134-40.e1. doi: 10.1016/j.fertnstert.2011.10.040. Epub 2011 Dec 2.

8.

The Impact of Endometriosis and Its Treatment on Ovarian Reserve.

Seyhan A, Ata B, Uncu G.

Semin Reprod Med. 2015 Nov;33(6):422-8. doi: 10.1055/s-0035-1567820. Epub 2015 Nov 23. Review.

PMID:
26594869
9.

Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications.

Broer SL, Broekmans FJ, Laven JS, Fauser BC.

Hum Reprod Update. 2014 Sep-Oct;20(5):688-701. doi: 10.1093/humupd/dmu020. Epub 2014 May 12. Review.

PMID:
24821925
10.

Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.

Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F.

Reprod Sci. 2015 May;22(5):519-26. doi: 10.1177/1933719114549856. Epub 2014 Sep 16. Review.

PMID:
25228631
11.

Race/ethnic disparities in reproductive age: an examination of ovarian reserve estimates across four race/ethnic groups of healthy, regularly cycling women.

Bleil ME, Gregorich SE, Adler NE, Sternfeld B, Rosen MP, Cedars MI.

Fertil Steril. 2014 Jan;101(1):199-207. doi: 10.1016/j.fertnstert.2013.09.015. Epub 2013 Oct 29.

12.

Anti-Müllerian hormone: clairvoyance or crystal clear?

Nelson SM, Anderson RA, Broekmans FJ, Raine-Fenning N, Fleming R, La Marca A.

Hum Reprod. 2012 Mar;27(3):631-6. doi: 10.1093/humrep/der446. Epub 2012 Jan 11.

PMID:
22238112
13.

Evaluation of serum anti-Mullerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICSI cycle.

Lin PY, Huang FJ, Kung FT, Chiang HJ, Lin YJ, Lin YC, Lan KC.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6245-53. eCollection 2014.

14.

Does preoperative antimüllerian hormone level influence postoperative pregnancy rate in women undergoing surgery for severe endometriosis?

Stochino-Loi E, Darwish B, Mircea O, Touleimat S, Millochau JC, Abo C, Angioni S, Roman H.

Fertil Steril. 2017 Mar;107(3):707-713.e3. doi: 10.1016/j.fertnstert.2016.12.013. Epub 2017 Jan 12.

PMID:
28089574
15.

Age at menarche: a predictor of diminished ovarian function?

Weghofer A, Kim A, Barad DH, Gleicher N.

Fertil Steril. 2013 Oct;100(4):1039-43. doi: 10.1016/j.fertnstert.2013.05.042. Epub 2013 Jun 27.

PMID:
23809497
16.

Impact of physical activity on ovarian reserve markers in normal, overweight and obese reproductive age women.

Surekha T, Himabindu Y, Sriharibabu M, Pandey AK.

Indian J Physiol Pharmacol. 2014 Apr-Jun;58(2):162-5.

PMID:
25509968
17.

Antimullerian hormone in cases of different reproductive pathologies.

Barbakadze L, Kristasashvili J.

Georgian Med News. 2014 Jul-Aug;(232-233):16-21.

PMID:
25214265
18.

Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.

Hvidman HW, Bentzen JG, Thuesen LL, Lauritsen MP, Forman JL, Loft A, Pinborg A, Nyboe Andersen A.

Hum Reprod. 2016 May;31(5):1034-45. doi: 10.1093/humrep/dew032. Epub 2016 Mar 9.

PMID:
26965431
19.

Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts.

Katz-Jaffe MG, Surrey ES, Minjarez DA, Gustofson RL, Stevens JM, Schoolcraft WB.

Obstet Gynecol. 2013 Jan;121(1):71-7. doi: http://10.1097/AOG.0b013e318278eeda.

PMID:
23262930
20.

Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone.

Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de Jong FH, van den Heuvel-Eibrink MM.

Hum Reprod. 2009 Apr;24(4):982-90. doi: 10.1093/humrep/den487. Epub 2009 Jan 18.

PMID:
19153092

Supplemental Content

Support Center